If you've been getting compounded tirzepatide, you've probably seen headlines about the FDA "banning" it — and it's genuinely hard to tell what's real. Here's the plain-English version of what changed in 2026 and what it actually means for you.
The background
Compounded GLP-1s exploded in popularity during the branded-drug shortages of 2022–2024. Compounding is normally allowed at large scale only when a drug is in official shortage. But the FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide's in 2025 — which closed the main door that had let pharmacies make these medications in bulk.
What the FDA proposed in 2026
On April 30, 2026, the FDA proposed keeping semaglutide, tirzepatide and liraglutide off the "503B bulks list." That list names the raw drug substances that large outsourcing facilities are allowed to compound from. The FDA's position is that there's no clinical need for these facilities to make GLP-1s from scratch now that the branded products are available. The agency took public comments through late June 2026 and will issue a final decision after reviewing them.
The short translation: this move targets large-scale, mass-production compounding, not every form of compounding everywhere.
What it doesn't do
This is the part the headlines usually skip. There are two kinds of compounders. 503B outsourcing facilities make big batches — those are the ones this proposal restricts. 503A pharmacies compound for one patient at a time against a specific prescription, and they can still compound a GLP-1 when there's a documented, patient-specific clinical reason — for example, a genuinely different dose than the commercial product, or a documented allergy to an inactive ingredient in the branded pen. So "compounded tirzepatide" isn't being switched off overnight; the lane is just getting much narrower and more scrutinized.
What this means for you
Practically, expect fewer providers offering cheap compounded GLP-1s purely for cost or convenience, and more scrutiny on the ones that do. That's not all bad — a lot of the sketchiest, lowest-quality operators lived in exactly that gap. But it does mean access can shift under your feet.
So make it a question you ask out loud before you commit to a provider:
- How do you source my medication — branded, or compounded, and from what kind of pharmacy?
- If the rules tighten, what's your plan to keep me on treatment without a gap?
- What happens to my price if a compounded option goes away?
A provider who answers those clearly is showing you the honest billing and continuity we weigh in our Care Standard. If you want a plain-language refresher on the terms in play, our GLP-1 glossary covers 503A, 503B and compounding. None of this is legal or medical advice — but it's the map you want in hand before your next refill.